necessary documentation has been completed for the
Post# of 72440
(Total Views: 227)
Posted On: 03/27/2019 10:18:47 AM
necessary documentation has been completed for the European Medicines Agency (EMA) March 15, 2019 submission cycle requesting Scientific Advice to advance Brilacidin oral rinse in a Phase 3 program for the prevention of severe Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients receiving chemoradiation. The documentation is being submitted to the EMA through IPIX Pharma, Ltd., the Innovation Pharmaceuticals Irish subsidiary.
What we don't know is where we're at with getting the U.S. trial set up. That news could hit any day now.
Bring on the partner!! Or licensing deal.
And no, I doubt very much Leo is one bit concerned about running out of money if he has this under control.
What we don't know is where we're at with getting the U.S. trial set up. That news could hit any day now.
Bring on the partner!! Or licensing deal.
And no, I doubt very much Leo is one bit concerned about running out of money if he has this under control.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼